Charlotte Wessel Skovlund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Charlotte Wessel Skovlund has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Søren Friis
Danish Cancer Institute, Danish Cancer Society , Copenhagen, Denmark
3 shared publicationsLina Steinrud Mørch
Cancer and Medicine, The Danish Cancer Institute, Copenhagen, Denmark
2 shared publications- Lina Steinrud Mørch
Cancer and Medicine, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark
2 shared publications Amalie Lykkemark Møller
Cancer and Medicine, The Danish Cancer Institute, Copenhagen, Denmark
1 shared publication- Amani Meaidi
Department of Gynaecology and Obstetrics, Nordsjællands Hospital, Hillerød, Denmark
1 shared publication - Caroline Hallas Hemmingsen
Danish Canc Inst, Virus Lifestyle & Genes, Strand Blvd 49, DK-2100 Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 5 January 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 38, 100813
Depression risk in users of different doses of levonorgestrel intrauterine systems: a nationwide prospective cohort study
- 5 January 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 38, 100813
Open AccessDepression risk in users of different doses of levonorgestrel intrauterine systems: a nationwide prospective cohort study
- 15 November 2023
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (4) , 530-538
Long-term aspirin use and cancer risk: a 20-year cohort study
Background: Long-term use of aspirin has been shown to reduce colorectal cancer risk, but the association remains inconclusive for individual noncolorectal cancers. We examined the association between long-term aspirin use and cancer risk in Denmark. Methods: Using nationwide registries, we followed individuals aged 40-70 years at baseline (January 1, 1997) for cancer diagnoses through 2018. We assessed low-dose (75-150 mg) aspirin use according to continuity, duration, and cumulative amount. In addition, we explored associations with consistent high-dose (500 mg) aspirin use. Using Cox regression, we estimated multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) with aspirin use for overall and site-specific cancer. Results: Among 1 909 531 individuals, 422 778 were diagnosed with cancer during mean follow-up of 18.2 years. Low-dose aspirin use did not reduce the hazard ratio for cancer overall irrespective of continuity and duration of use (continuous use: HR = 1.04, 95% CI = 1.03 to 1.06). However, long-term (≥5 or ≥10 years) use was associated with at least 10% reductions in hazard ratios for several cancer sites: colon, rectum, esophagus, stomach, liver, pancreas, small intestine, head and neck, brain tumors, meningioma, melanoma, thyroid, non-Hodgkin lymphoma, and leukemia. Substantially elevated hazard ratios were found for lung and bladder cancer. In secondary analyses, consistent high-dose aspirin use was associated with reduced hazard ratios for cancer overall (HR = 0.89, 95% CI = 0.85 to 0.93) and for several cancer sites. Conclusion: Long-term low-dose aspirin use was associated with slight to moderately reduced risks for several cancers but not for cancer overall owing to increased risk for some common cancers. Similar or slightly stronger inverse associations were observed for consistent use of high-dose aspirin.
- 15 November 2023
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (4) , 530-538
Long-term aspirin use and cancer risk: a 20-year cohort study
Background: Long-term use of aspirin has been shown to reduce colorectal cancer risk, but the association remains inconclusive for individual noncolorectal cancers. We examined the association between long-term aspirin use and cancer risk in Denmark. Methods: Using nationwide registries, we followed individuals aged 40-70 years at baseline (January 1, 1997) for cancer diagnoses through 2018. We assessed low-dose (75-150 mg) aspirin use according to continuity, duration, and cumulative amount. In addition, we explored associations with consistent high-dose (500 mg) aspirin use. Using Cox regression, we estimated multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) with aspirin use for overall and site-specific cancer. Results: Among 1 909 531 individuals, 422 778 were diagnosed with cancer during mean follow-up of 18.2 years. Low-dose aspirin use did not reduce the hazard ratio for cancer overall irrespective of continuity and duration of use (continuous use: HR = 1.04, 95% CI = 1.03 to 1.06). However, long-term (≥5 or ≥10 years) use was associated with at least 10% reductions in hazard ratios for several cancer sites: colon, rectum, esophagus, stomach, liver, pancreas, small intestine, head and neck, brain tumors, meningioma, melanoma, thyroid, non-Hodgkin lymphoma, and leukemia. Substantially elevated hazard ratios were found for lung and bladder cancer. In secondary analyses, consistent high-dose aspirin use was associated with reduced hazard ratios for cancer overall (HR = 0.89, 95% CI = 0.85 to 0.93) and for several cancer sites. Conclusion: Long-term low-dose aspirin use was associated with slight to moderately reduced risks for several cancers but not for cancer overall owing to increased risk for some common cancers. Similar or slightly stronger inverse associations were observed for consistent use of high-dose aspirin.
- Open Access
In Utero Exposure to Hormonal Contraception and Mortality in Offspring with and without Cancer: A Nationwide Cohort Study
Approximately 400 million women of reproductive age use hormonal contraceptives worldwide. Eventually, pregnancy sometimes occurs due to irregular use. Use in early pregnancy is found to be associated with child morbidities including cancer, the main reason for disease-related death in children. Here, we add the missing piece about in utero exposure to hormonal contraception and mortality in offspring, including assessments of prognosis in children with cancer. In utero exposure to hormonal contraception may be associated with death since we found a hazard ratio (HR) of 1.22 (95% confidence interval (CI) 1.01–1.48) compared to children of mothers with previous use. The HRs were 1.22 (95% CI 0.99–1.13) for oral combined products and 2.92 (95% CI 1.21–7.04) for non-oral progestin-only products. A poorer prognosis was also found in exposed children with leukemia (3.62 (95% CI: 1.33–9.87)). If causal, hormonal contraception in pregnancy seems detrimental for offspring health and a marker of poorer prognosis in children with leukemia.
Open AccessIn Utero Exposure to Hormonal Contraception and Mortality in Offspring with and without Cancer: A Nationwide Cohort Study
Approximately 400 million women of reproductive age use hormonal contraceptives worldwide. Eventually, pregnancy sometimes occurs due to irregular use. Use in early pregnancy is found to be associated with child morbidities including cancer, the main reason for disease-related death in children. Here, we add the missing piece about in utero exposure to hormonal contraception and mortality in offspring, including assessments of prognosis in children with cancer. In utero exposure to hormonal contraception may be associated with death since we found a hazard ratio (HR) of 1.22 (95% confidence interval (CI) 1.01–1.48) compared to children of mothers with previous use. The HRs were 1.22 (95% CI 0.99–1.13) for oral combined products and 2.92 (95% CI 1.21–7.04) for non-oral progestin-only products. A poorer prognosis was also found in exposed children with leukemia (3.62 (95% CI: 1.33–9.87)). If causal, hormonal contraception in pregnancy seems detrimental for offspring health and a marker of poorer prognosis in children with leukemia.
- Open Access
- 12 January 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (5) , 658-661
Drop in cancer diagnosis during the COVID-19 pandemic in Denmark: assessment of impact during 2020
Several countries have reported a decline in cancer diagnoses during the COVID-19 pandemic [1–7]. The European Cancer Organisation estimated that clinicians diagnosed 1.5 million fewer cancer patie...
- 12 January 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (5) , 658-661
Open AccessDrop in cancer diagnosis during the COVID-19 pandemic in Denmark: assessment of impact during 2020
Several countries have reported a decline in cancer diagnoses during the COVID-19 pandemic [1–7]. The European Cancer Organisation estimated that clinicians diagnosed 1.5 million fewer cancer patie...
- 7 December 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 60 (1) , 20-23
Hidden morbidities: drop in cancer diagnoses during the COVID-19 pandemic in Denmark
Following the first case of acute respiratory syndrome coronavirus 2 (SARS-CoV-2, known as COVID-19) in Denmark at the end of February 2020, wide-spread social distancing was implemented and societ...
- 7 December 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 60 (1) , 20-23
Hidden morbidities: drop in cancer diagnoses during the COVID-19 pandemic in Denmark
Following the first case of acute respiratory syndrome coronavirus 2 (SARS-CoV-2, known as COVID-19) in Denmark at the end of February 2020, wide-spread social distancing was implemented and societ...
- Open Access
- 16 September 2013
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 92 (10) , 1135-1142
Venous thromboembolism in pregnancy and the puerperal period: a study of 1210 events
Objective: The aim of this study was to describe venous thromboembolism (VTE) in pregnancy and the puerperal period, and to validate diagnoses of VTE.Design: Historical cohort study.Population: All pregnancies in Denmark from 1995 to 2009.Methods: VTE diagnoses were retrieved from national registries.Main outcome measures: Positive predictive value of a VTE diagnoses diagnosed during pregnancy or the puerperal period. Location of VTE. Incidence rate of confirmed, validated diagnoses of VTE and on all retrieved diagnoses of VTE.Results: In 1 297 037 pregnancies, 1436 women had a first‐ever VTE diagnosis. Hospital records were retrieved for 1210 women (84.3%). Almost all women had relevant clinical symptoms and in 796 (65.8%), the diagnosis were confirmed by a positive diagnostic test or by instituted anticoagulation treatment. In all, 72.6, 53.7, 58.5 and 79.1% of the diagnoses were confirmed in the first, second, third trimester and the puerperal period, respectively. The 796 cases of VTE included 624 women with deep venous thrombosis only and 133 with pulmonary embolisms. Deep venous thrombosis was located in the left lower limb in 83.8% in pregnancy, compared with 67.9% in the puerperal period.Conclusions: The vast majority of women with a registered diagnosis of VTE had relevant symptoms. Diagnoses of VTE were confirmed in the medical records in two of three women. VTE diagnoses were most often confirmed when made in the first trimester and in the puerperal period. Left‐sided deep venous thrombosis was the predominant type of VTE in pregnancy and the puerperal period.
- 16 September 2013
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 92 (10) , 1135-1142
Open AccessVenous thromboembolism in pregnancy and the puerperal period: a study of 1210 events
Objective: The aim of this study was to describe venous thromboembolism (VTE) in pregnancy and the puerperal period, and to validate diagnoses of VTE.Design: Historical cohort study.Population: All pregnancies in Denmark from 1995 to 2009.Methods: VTE diagnoses were retrieved from national registries.Main outcome measures: Positive predictive value of a VTE diagnoses diagnosed during pregnancy or the puerperal period. Location of VTE. Incidence rate of confirmed, validated diagnoses of VTE and on all retrieved diagnoses of VTE.Results: In 1 297 037 pregnancies, 1436 women had a first‐ever VTE diagnosis. Hospital records were retrieved for 1210 women (84.3%). Almost all women had relevant clinical symptoms and in 796 (65.8%), the diagnosis were confirmed by a positive diagnostic test or by instituted anticoagulation treatment. In all, 72.6, 53.7, 58.5 and 79.1% of the diagnoses were confirmed in the first, second, third trimester and the puerperal period, respectively. The 796 cases of VTE included 624 women with deep venous thrombosis only and 133 with pulmonary embolisms. Deep venous thrombosis was located in the left lower limb in 83.8% in pregnancy, compared with 67.9% in the puerperal period.Conclusions: The vast majority of women with a registered diagnosis of VTE had relevant symptoms. Diagnoses of VTE were confirmed in the medical records in two of three women. VTE diagnoses were most often confirmed when made in the first trimester and in the puerperal period. Left‐sided deep venous thrombosis was the predominant type of VTE in pregnancy and the puerperal period.